News | January 23, 2026
Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator
This marks the second indication for which gumokimab has gained NDA review acceptance
This marks the second indication for which gumokimab has gained NDA review acceptance
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
Subscribe To Our Newsletter & Stay Updated
